A Model to Predict In-Hospital Mortality in HIV/AIDS Patients with Pneumocystis Pneumonia in China: The Clinical Practice in Real World
Table 1
Baseline characteristics of HIV/AIDS patient with PCP in the study cohort.
Variables
Total n=1001
Derivation cohort n=801
Validation cohort n=200
p value
Age (years)
⩾50
188 (18.8%)
156 (19.5%)
32 (16.0%)
0.260
<50
813 (81.2%)
645 (80.5%)
168 (84.0%)
Gender
Female
77 (7.7%)
61 (7.6%)
16 (8.0%)
0.855
Male
924 (92.3%)
740 (92.4%)
184 (92.0%)
Transmission route
Homosexual
94 (9.4%)
71 (8.9%)
23 (11.5%)
0.484
Heterosexual
272 (27.2%)
218 (27.2%)
54 (27.0%)
Blood transfusion
11 (1.1%)
7 (0.9%)
4 (2.0%)
Intravenous drug
7 (0.7%)
6 (0.7%)
1 (0.5%)
Unknown
617 (61.6%)
499 (62.3%)
118 (59.0%)
Marriage
Married
542 (54.1%)
439 (54.8%)
103 (51.5%)
0.401
Unmarried
459 (45.9%)
362 (45.3%)
97 (48.5%)
Laboratory results
HGB (g/L)
Median (Q1, Q3)
120 (107, 133)
120 (107, 134)
119.7(107.3, 131)
0.403
>90g/L
918 (91.7%)
737 (92.0%)
181 (90.5%)
0.488
≦90g/L
83 (8.3%)
64 (8.0%)
19 (9.5%)
ALB) (g/L)
Median (Q1, Q3
31.8(28.3, 34.8)
31.7(28.3, 34.9)
32.1(28.5, 34.6)
0.539
>30g/L
646 (64.5%)
519 (64.8%)
127 (63.5%)
0.732
⩽30g/L
355 (35.5%)
282 (35.2%)
73 (36.5%)
CD4 (cells/ul)
Median (Q1, Q3)
21 (10, 47)
35.2 (10, 46)
41.6 (9, 53.8)
0.082
>50cells/ul
236 (23.6%)
183 (22.8%)
53 (26.5%)
0.276
≦50cells/ul
765 (76.4%)
618 (77.2%)
147 (73.5%)
LDH (IU/L)
Median (Q1, Q3)
334.1(252.8, 456.5)
336.8(251.4, 457.1)
321.8(259.2, 449.2)
0.198
⩾350 IU/L
456 (45.6%)
372 (46.4%)
84 (42.0%)
0.259
<350 IU/L
545 (54.4%)
429 (53.6%)
116 (58.0%)
Partial pressure of oxygen
>70mmHg
541 (54.0%)
434 (54.2%)
107 (53.5%)
0.863
⩽70mmHg
460 (46.0%)
367 (45.8%)
93 (46.5%)
Vital signs
Respiratory rate
⩾30 times/min
142 (14.2%)
115 (14.4%)
27 (13.5%)
0.756
<30 times/min
859 (85.8%)
686 (85.6%)
173 (86.5%)
Heart rate
⩾130 times/min
58 (5.8%)
42 (5.2%)
16 (8.0%)
0.136
<130 times/min
943 (94.2%)
759 (94.8%)
184 (92.0%)
Duration of ART prior to admission
ART-naive
898 (89.7%)
720 (89.9%)
178 (89.0%)
0.618
<6 months
86 (8.6%)
69 (8.6%)
17 (8.5%)
>6 months
17 (1.7%)
12 (1.5%)
5 (2.5%)
Later admission to ICU
Yes
183 (18.3%)
147 (18.4%)
36 (18.0%)
0.908
NO
818 (81.7%)
654 (81.6%)
164 (82.0%)
Comorbidities
Bacterial pneumonitis
Yes
832 (83.1%)
663 (82.8%)
169 (84.5%)
0.559
NO
169 (16.9%)
138 (17.2%)
31 (15.5%)
CMV pneumonitis
Yes
385 (38.5%)
304 (38%)
81 (40.5%)
0.508
NO
616 (61.5%)
497 (62%)
119 (59.5%)
Cryptococcal pneumonitis
Yes
19 (1.9%)
17 (2.1%)
2 (1.0%)
0.298
NO
982 (98.1%)
784 (97.9%)
198 (99.0%)
Fungal pneumonia
Yes
209 (20.9%)
163 (20.3%)
46 (23.0%)
0.409
NO
792 (79.1%)
638 (79.7%)
154 (77.0%)
Pulmonary tuberculosis
Yes
148 (14.8%)
110 (13.7%)
38 (19.0%)
0.060
NO
853 (85.2%)
691 (86.3%)
162 (81.0%)
Severe pneumonia
Yes
148 (14.8%)
115 (14.4%)
33 (16.5%)
0.445
NO
853 (85.2%)
686 (85.6%)
167 (83.5%)
Pneumothorax
Yes
41 (4.0%)
34 (4.2%)
7 (3.5%)
0.635
NO
960 (96.0%)
767 (95.8%)
193 (96.5%)
CNS infection
Yes
54 (5.4%)
43 (5.4%)
11 (5.5%)
0.941
NO
947 (94.6%)
758 (94.6%)
189 (94.5%)
Cardiovascular disease
Yes
64 (6.4%)
46 (5.7%)
18 (9.0%)
0.092
NO
937 (93.6%)
755 (94.3%)
182 (91.0%)
Malignancies
Yes
27 (2.7%)
23 (2.9%)
4 (2.0%)
0.496
NO
974 (97.3%)
778 (97.1%)
196 (98.0%)
Note. HGB: hemoglobin; ALB: albumin; LDH: lactate dehydrogenase; ART: antiretroviral therapy; ICU: intensive care unit; CMV: cytomegalovirus; CNS: central nervous system. Median (Q1, Q3): median based on 25th and 75th percentiles.
